Little over year after IPO, biotech's majority owner wants to buy it all
August 12, 2019 at 16:42 PM EDT
BridgeBio already owns two-thirds of Eidos, the rare disease spinout from Stanford University labs.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.